PharmaPoint: Hepatitis C Virus – Spain Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 127

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – Spain Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The main drivers of growth in the HCV market in Spain are expected to include an increase in HCV awareness and the launch of next-generation HCV regimens.

Incivo and Merck’s Victrelis were the first DAA HCV therapies launched in Spain. Both therapies had significantly improved efficacy compared with the front-line therapy for HCV GT1 in Spain at the time, which was a combination of peginterferon and ribavirin. Incivo quickly became the standard of care for HCV GT1 in Spain.

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Spain from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Spain HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Spain

PharmaPoint: Hepatitis C Virus – Spain Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 Spain 21
4.3.1 Diagnosis 21
4.3.2 Clinical Practice 22

5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 23
5.3 Product Profiles - Major Brands 25
5.3.1 Incivek (telaprevir) 25
5.3.2 Victrelis (boceprevir) 30
5.3.3 Pegasys (peginterferon alfa-2a) 34
5.3.4 PegIntron (peginterferon alfa-2b) 38
5.3.5 Copegus, Rebetol, and Generic Ribavirin 42
5.3.6 Therapeutic Class: Interferon 44

6 Opportunity and Unmet Need 45
6.1 Overview 45
6.2 Unmet Needs 46
6.2.1 Unmet Need: Treatment Tolerability 46
6.2.2 Unmet Need: Efficacy 46
6.2.3 Unmet Need: Disease Awareness 47
6.2.4 Unmet Need: Treatment Cost 48
6.2.5 Unmet Need: Shorter Treatment Duration 48
6.2.6 Unmet Need: Simplified Treatment Regimens 49
6.3 Unmet Needs Gap Analysis 49
6.4 Opportunities 50
6.4.1 Opportunity: Pan-genotypic HCV Regimen 50
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 50
6.4.3 Opportunity: Involvement of Immune System 51

7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Drugs in Clinical Development 53
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 54
7.2.2 Simeprevir 64
7.2.3 ABT-450 plus ABT-267 and ABT-333 71
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 78
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 86
7.2.6 Other Drug Classes 94

8 Market Outlook 97
8.1 Spain 97
8.1.1 Forecast 97
8.1.2 Key Events 101
8.1.3 Drivers and Barriers 101

9 Appendix 104
9.1 Bibliography 104
9.2 Abbreviations 112
9.3 Methodology 114
9.4 Forecasting Methodology 114
9.4.1 Percent Drug-Treated Patients 114
9.4.2 Patient Warehousing 115
9.4.3 Drugs Included in Each Therapeutic Class 115
9.4.4 Launch and Patent Expiry Dates 116
9.4.5 General Pricing Assumptions 117
9.4.6 Individual Drug Assumptions 117
9.4.7 Generic Erosion 119
9.4.8 Selection of Pipeline Agents 119
9.4.9 Pricing of Pipeline Agents 120
9.5 Physicians and Specialists Included in this Study 123
9.6 Survey of Prescribing Physicians 125
9.7 About the Authors 126
9.7.1 Author 126
9.7.2 Global Head of Healthcare 126
9.8 About GlobalData 127
9.9 Contact Us 127
9.10 Disclaimer 127

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 20
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 24
Table 8: Product Profile - Incivek 26
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 26
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 27
Table 11: Common Incivek Adverse Drug Reactions 28
Table 12: Incivek SWOT Analysis, 2012 29
Table 13: Product Profile - Victrelis 30
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 31
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 32
Table 16: Victrelis SWOT Analysis, 2012 34
Table 17: Product Profile - Pegasys 35
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 36
Table 19: Pegasys SWOT Analysis, 2012 38
Table 20: Product Profile - PegIntron 39
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 40
Table 22: PegIntron SWOT Analysis, 2012 41
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 43
Table 24: Ribavirin SWOT Analysis, 2012 44
Table 25: Summary of Minor Therapeutic Classes, 2012 44
Table 26: Overall Unmet Needs - Current Level of Attainment 45
Table 27: Clinical Unmet Needs - Gap Analysis, 2012 49
Table 28: HCV - Pipeline, 2012 53
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 54
Table 30: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 56
Table 31: Product Profile - Sofosbuvir 57
Table 32: Sofosbuvir's Most Common Adverse Effects 60
Table 33: Sofosbuvir SWOT Analysis, 2012 64
Table 34: Janssen's Simeprevir Ongoing Clinical Trials of Interest 65
Table 35: Product Profile - Simeprevir 66
Table 36: PILLAR Clinical Trial Results 66
Table 37: Adverse Events Observed in PILLAR Clinical Trial 67
Table 38: Simeprevir SWOT Analysis, 2012 70
Table 39: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 72
Table 40: Product Profile - AbbVie Combination Therapy 73
Table 41: AVIATOR Clinical Trial Results 73
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 77
Table 43: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 79
Table 44: Product Profile - Faldaprevir 80
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 81
Table 46: Faldaprevir SWOT Analysis, 2012 85
Table 47: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 87
Table 48: Product Profile - Daclatasvir 88
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 88
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 89
Table 51: Daclatasvir Triple Therapy Adverse Events 90
Table 52: Daclatasvir SWOT Analysis, 2012 93
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 94
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 95
Table 55: Sales Forecasts ($m) for HCV in Spain, 2012-2022 99
Table 56: Key Events Impacting Sales for HCV in Spain, 2012 101
Table 57: Spanish HCV Market - Drivers and Barriers, 2012 101
Table 58: Key Launch Dates 116
Table 59: Key Patent Expiries 116
Table 60: Physicians Surveyed, By Country 125

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 53
Figure 4: Sales for HCV Therapeutics in Spain by Drug Class, 2012-2022 100

  • Global Dental Implants Market Driven by Demand in Cosmetic Dentistry
    The global market for dental implants has been witnessing steady growth in the last couple of years due to increased demand for cosmetic dentistry and rise in incidences of dental disorders. People’s awareness about aesthetic dentistry procedures has increased in recent years, which is also fueling the growth of the dental implant market. With economic [...]
  • Air Traffic Management and Control Market Driven by Technological Advancement
    The global market for air traffic management and control has grown steadily in the last couple of years with increase in air traffic volume and congestion. Air Traffic Control (ATC) consists of an elaborate system of ground stations, radar arrays and professional air traffic controllers. With increase in air travel for business and leisure, as [...]
  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Global Anti-Obesity Drugs Market 2015-2019
    Published: 26-Nov-2014        Price: US $2500 Onwards        Pages: 78
    Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. TechNavio's analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019. Covered in this Report The Global Anti-obesity Drugs market can be divided into......
  • China Pharmaceutical Excipients Industry Report, 2014-2017
    Published: 20-Nov-2014        Price: US $2300 Onwards        Pages: 101
    Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment. China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-......
  • Opportunity Analyzer: Celiac Disease – Opportunity Analysis and Forecast to 2018
    Published: 19-Nov-2014        Price: US $7995 Onwards        Pages: 166
    There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2......
  • Hepatitis B – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 317
    Global Markets Direct's, ‘Hepatitis B Pipeline Review, H2 2014', provides an overview of the Hepatitis B's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved ......
  • Grass Pollen Allergy – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 61
    Global Markets Direct's, ‘Grass Pollen Allergy Pipeline Review, H2 2014', provides an overview of the Grass Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also re......
  • Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 87
    Global Markets Direct's, ‘Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Review, H2 2014', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ......
  • Treatment Resistant Depression – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 57
    Global Markets Direct's, ‘Treatment Resistant Depression Pipeline Review, H2 2014', provides an overview of the Treatment Resistant Depression's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ......
  • Ragweed Allergy – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 45
    Global Markets Direct's, ‘Ragweed Allergy Pipeline Review, H2 2014', provides an overview of the Ragweed Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key playe......
  • Microscopic Polyangiitis (MPA) – Pipeline Review, H2 2014
    Published: 18-Nov-2014        Price: US $2000 Onwards        Pages: 48
    Global Markets Direct's, ‘Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2014', provides an overview of the Microscopic Polyangiitis (MPA)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured new......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs